Recent advances in pharmacological treatment of irritable bowel syndrome

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 8867-8885

  Lazaraki, Georgia ^a   Chatzimavroudis, Grigoris ^a   Katsinelos, Panagiotis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Constipation; Diarrhea; Irritable bowel syndrome; Irritable bowel syndrome constipation; Irritable bowel syndrome treatment; Irritable bowel syndrome diarrhea; Irritable bowel syndrome pain

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALOSETRON; ALVERINE; BILE ACID SEQUESTRANT; CHENODEOXYCHOLIC ACID; CILANSETRON; CIMETROPIUM; CISAPRIDE; CROFELEMER; GLUCAGON LIKE PEPTIDE 1; KETOTIFEN; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MEBEVERINE; MESALAZINE; OTILONIUM BROMIDE; PINAVERIUM; PRIFINIUM BROMIDE; RAMOSETRON; RENZAPRIDE; RIFAXIMIN; ROCIVERINE; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SPASMOLYTIC AGENT; TEGASEROD; TRIMEBUTINE; GASTROINTESTINAL AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; DRUG DESIGN; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL MOTILITY; HUMAN; IRRITABLE COLON; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); ANIMAL; CONSTIPATION; DIARRHEA; IRRITABLE BOWEL SYNDROME; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ABDOMINAL PAIN; ANIMALS; CONSTIPATION; DIARRHEA; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; RISK FACTORS; TREATMENT OUTCOME;

EID: 84905380198     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.8867     Document Type: Review

References (149)

1. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-607 [PMID: 12650794 DOI: 10.1111/j.1572-0241.2003.07296.x]
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/j.gastro.2005.11.061]
3. Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol 2009; 2: 221-238 [PMID: 21180545 DOI: 10.1177/1756283X09104794]
4. Crowell MD, Harris L, Jones MP, Chang L. New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep 2005; 7: 272-279 [PMID: 16042910 DOI: 10.1007/s11894-005-0019-8]
5. Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 21-43 [PMID: 21333899 DOI: 10.1016/j.gtc.2010.12.004]
6. Pimentel M, Chang C. Inflammation and microflora. Gastroenterol Clin North Am 2011; 40: 69-85 [PMID: 21333901 DOI: 10.1016/j.gtc.2010.12.010]
7. Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol 2011; 17: 4251-4257 [PMID: 22090780 DOI: 10.3748/wjg.v17.i38.4251]
8. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22 : 293-e82 [PMID: 20025692 DOI: 10.1111/j.1365-2982.2009.01442.x]
9. Deiteren A, Camilleri M, Burton D, McKinzie S, Rao A, Zinsmeister AR. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig Dis Sci 2010; 55 : 384-391 [PMID: 19949866 DOI: 10.1007/s10620-009-1041-8]
10. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23 : 191-196 [PMID: 16393297 DOI: 10.1111/j.1365-2036.2006.02705.x]
11. Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis 2010; 12: 1131-1138 [PMID: 19575740 DOI: 10.1111/j.1463-1318.2009.01990.x]
12. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108: 1508-1515 [PMID: 23835436 DOI: 10.1038/ajg.2013.197]
13. Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010; 86 : 760-765 [PMID: 20307554 DOI: 10.1016/j.lfs.2010.03.015]
14. Shailubhai K . Therapeutic applications of guanylate cyclase-C receptor agonists. Curr Opin Drug Discov Devel 2002; 5: 261-268 [PMID: 11926132]
15. Maneerattanaporn M, Chang L, Chey WD. Emerging pharmacological therapies for the irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 223-243 [PMID: 21333909 DOI: 10.1016/j.gtc.2010.12.002]
16. Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-768 [PMID: 17854590]
17. Johnston JM, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, MacDougall JE, Antonelli SM, Currie MG. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009; 104: 125-132 [PMID: 19098860 DOI: 10.1038/ajg.2008.59]
18. Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138 : 886-895.e1 [PMID: 20045700 DOI: 10.1053/j.gastro.2009.12.050]
19. Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-1886.e2 [PMID: 20801122 DOI: 10.1053/j.gastro.2010.08.041]
20. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107 : 1702-1712 [PMID: 22986437 DOI: 10.1038/ajg.2012.254]
21. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107 : 1714-1724; quiz p.1725 [PMID: 22986440 DOI: 10.1038/ajg.2012.255]
22. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37: 49-61 [PMID: 23116208 DOI: 10.1111/apt.12123]
23. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1084-1092.e3; quiz e68 [PMID: 23644388 DOI: 10.1016/j.cgh.2013.04.032]
24. Hasler WL. Serotonin and the GI tract. Curr Gastroenterol Rep 2009; 11: 383-391 [PMID: 19765366 DOI: 10.1007/s11894-009-0058-7]
25. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-670 [PMID: 12692050 DOI: 10.1136/gut.52.5.663]
26. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357 [PMID: 15822040]
27. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43 [PMID: 16401466 DOI: 10.1053/j.gastro.2005.09.031]
28. Zuo XL, Li YQ, Yang XZ, Guo M, Guo YT, Lu XF, Li JM, Desmond PV. Plasma and gastric mucosal 5-hydroxytryptamine concentrations following cold water intake in patients with diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007; 22: 2330-2337 [PMID: 18265445 DOI: 10.1111/j.1440-1746.2006.04772.x]
29. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132 : 397-414 [PMID: 17241888 DOI: 10.1053/j.gastro.2006.11.002]
30. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-380 [PMID: 9679042 DOI: 10.1016/S0016-5085(98)70203-3]
31. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Lüchinger S, Bertold R, Maecke H, Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-1751 [PMID: 11683688 DOI: 10.1046/j.1365-2036.2001.01103.x]
32. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118 : 463-468 [PMID: 10702196 DOI: 10.1016/S0016-5085(00)70251-4]
33. Jiao HM, Xie PY. Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity. World J Gastroenterol 2004; 10: 2836-2841 [PMID: 15334681]
34. Sabaté JM, Bouhassira D, Poupardin C, Wagner A, Loria Y, Coffin B. Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008; 20: 134-141 [PMID: 18004988 DOI: 10.1111/j.1365-2982.2007.01030.x]
35. Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Rüegg P. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-1666 [PMID: 11564007 DOI: 10.1046/j.1365-2036.2001.01094.x]
36. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, Rüegg P, Lefkowitz M. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-1888 [PMID: 12390096 DOI: 10.1046/j.1365-2036.2002.01372.x]
37. Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008; 103 : 1217-1225 [PMID: 18477346 DOI: 10.1111/j.1572-0241.2008.01808.x]
38. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52 : 671-676 [PMID: 12692051 DOI: 10.1136/gut.52.5.671]
39. Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Rüegg P, Jones J, Wagner A. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 119-126 [PMID: 15000272 DOI: 10.1080/00365520310006748]
40. Tougas G, Snape WJ, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701-1708 [PMID: 12269961 DOI: 10.1046/j.1365-2036.2002.01347.x]
41. Saad RJ. Peripherally acting therapies for the treatment of irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 163-182 [PMID: 21333906 DOI: 10.1016/j.gtc.2010.12.008]
42. Thompson CA. Novartis suspends tegaserod sales at FDA' s request. Am J Health Syst Pharm 2007; 64 : 1020 [PMID: 17494895 DOI: 10.2146/news070044]
43. Serebruany VL, El Mouelhi M, Pfannkuche HJ, Rose K, Marro M, Angiolillo DJ. Investigations on 5-HT4 receptor expression and effects of tegaserod on human platelet aggregation in vitro. Am J Ther 2010; 17: 543-552 [PMID: 19797939 DOI: 10.1097/MJT.0b013e3181b63f21]
44. Liu Z, Sakakibara R, Odaka T, Uchiyama T, Uchiyama T, Yamamoto T, Ito T, Asahina M, Yamaguchi K, Yamaguchi T, Hattori T. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20: 680-686 [PMID: 15719424 DOI: 10.1002/mds.20387]
45. Kim HS, Choi EJ, Park H. The effect of mosapride citrate on proximal and distal colonic motor function in the guineapig in vitro. Neurogastroenterol Motil 2008; 20: 169-176 [PMID: 17931343 DOI: 10.1111/j.1365-2982.2007.00996.x]
46. Kojima Y, Fujii H, Katsui R, Nakajima Y, Takaki M. Enhancement of the intrinsic defecation reflex by mosapride, a 5-HT4 agonist, in chronically lumbosacral denervated guinea pigs. J Smooth Muscle Res 2006; 42: 139-147 [PMID: 17159330 DOI: 10.1540/jsmr.42.139]
47. Kojima Y, Nakagawa T, Katsui R, Fujii H, Nakajima Y, Takaki M. A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectoanal reflexes after removal of extrinsic nerves in guinea pigs. Am J Physiol Gastrointest Liver Physiol 2005; 289: G351-G360 [PMID: 15817810 DOI: 10.1152/ajpgi.00532.2004]
48. Kanazawa M, Watanabe S, Tana C, Komuro H, Aoki M, Fukudo S. Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 754-e332 [PMID: 21615623 DOI: 10.1111/j.1365-2982.2011.01732.x]
49. Lembo AJ, Cremonini F, Meyers N, Hickling R. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther 2010; 31: 979-990 [PMID: 20163375 DOI: 10.1111/j.1365-2036.2010.04265.x]
50. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007; 41 : 345-351 [PMID: 17413599 DOI: 10.1097/01.mcg.0000225665.68920.df]
51. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 2009; 137: 976-985 [PMID: 19454284 DOI: 10.1053/j.gastro.2009.05.037]
52. Chan WW, Mashimo H. Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway. J Neurogastroenterol Motil 2013; 19 : 312-318 [PMID: 23875097 DOI: 10.5056/jnm.2013.19.3.312]
53. Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, McKinzie S, Zinsmeister AR. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-G947 [PMID: 16603730 DOI: 10.1152/ajpgi.00264.2005]
54. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007; 25: 1351-1361 [PMID: 17509103 DOI: 10.1111/j.1365-2036.2007.03320.x]
55. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-177 [PMID: 17916109 DOI: 10.1111/j.1572-0241.2007.01524.x]
56. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010; 55: 1090-1097 [PMID: 20012484]
57. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-696 [PMID: 18248656 DOI: 10.1111/j.1365-2036.2008.03629.x]
58. Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011; 23: 544-e205 [PMID: 21303430 DOI: 10.1111/j.1365-2982.2011.01668.x]
59. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-341 [PMID: 19006537 DOI: 10.1111/j.1365-2036.2008.03881.x]
60. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012; 35: 587-599 [PMID: 22251419 DOI: 10.1111/j.1365-2036.2011.04983.x]
61. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidencebased position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1: S1-S35 [PMID: 19521341 DOI: 10.1038/ajg.2008.122]
62. Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs 1981; 21: 90-119 [PMID: 7009140 DOI: 10.2165/00003495-198121020-00002]
63. Mitchell WD, Findlay JM, Prescott RJ, Eastwood MA, Horn DB. Bile acids in the diarrhoea of ileal resection. Gut 1973; 14: 348-353 [PMID: 4736774 DOI: 10.1136/gut.14.5.348]
64. Aldini R, Roda A, Festi D, Sama C, Mazzella G, Bazzoli F, Morselli AM, Roda E, Barbara L. Bile acid malabsorption and bile acid diarrhea in intestinal resection. Dig Dis Sci 1982; 27: 495-502 [PMID: 6806052 DOI: 10.1007/BF01296727]
65. Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139 : 1549-1558, 1558.e1 [PMID: 20691689 DOI: 10.1053/j.gastro.2010.07.052]
66. Kirwan WO, Smith AN, Mitchell WD, Falconer JD, Eastwood MA. Bile acids and colonic motility in the rabbit and the human. Gut 1975; 16: 894-902 [PMID: 1193418 DOI: 10.1136/gut.16.11.894]
67. Mok HY, Bell GD, Dowling RH. Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet 1974; 2: 253-257 [PMID: 4135688 DOI: 10.1016/S0140-6736(74)91415-9]
68. Caspary WF, Meyne K. Effects of chenodeoxy- and ursodeoxycholic acid on absorption, secretion and permeability in rat colon and small intestine. Digestion 1980; 20: 168-174 [PMID: 7390046]
69. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R, Zinsmeister AR. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-165 [PMID: 19879973 DOI: 10.1016/j.cgh.2009.10.020]
70. Fromm H, Roat JW, Gonzalez V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Gastroenterology 1983; 85: 1257-1264 [PMID: 6354826]
71. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-247 [PMID: 6365490 DOI: 10.1007/BF01296258]
72. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987; 130: 81-84 [PMID: 3306904 DOI: 10.3109/00365528709091004]
73. Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987; 130 : 77-80 [PMID: 3306903 DOI: 10.3109/00365528709091003]
74. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-468 [PMID: 8734343 DOI: 10.3109/00365529609006766]
75. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355 : 1035-1040 [PMID: 10744088 DOI: 10.1016/S0140-6736(00)02033-X]
76. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-1740 [PMID: 11485506 DOI: 10.1001/archinte.161.14.1733]
77. Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 455-459 [PMID: 11232690 DOI: 10.1111/j.1572-0241.2001.03525.x]
78. Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-2670 [PMID: 11569692 DOI: 10.1111/j.1572-0241.2001.04128.x]
79. Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther 2012; 36 : 437-448 [PMID: 22779693 DOI: 10.1111/j.1365-2036.2012.05208.x]
80. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30: 884-901 [PMID: 18555935 DOI: 10.1016/j.clinthera.2008.05.002]
81. Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6: 545-555 [PMID: 18242143 DOI: 10.1016/j.cgh.2007.12.015]
82. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-1843; quiz 1844 [PMID: 19471254 DOI: 10.1038/ajg.2009.223]
83. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 2010; 105: 866-875 [PMID: 20197759 DOI: 10.1038/ajg.2010.25]
84. Ohta M, Suzuki T, Nagashima S, Tokunaga T, Miyata K, Mase T. Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. IV. Synthesis and pharmacological evaluation of the oxidation products of (-)-(R)-5-[(1-methyl-1H-indol-3-yl)carbonyl] -4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060: ramosetron). Chem Pharm Bull (Tokyo) 1996; 44: 1717-1722 [PMID: 8855366 DOI: 10.1248/cpb.44.1707]
85. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008; 77: 225-235 [PMID: 18667823 DOI: 10.1159/000150632]
86. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1202-1211 [PMID: 18618371 DOI: 10.1080/00365520802240255]
87. Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011; 23: 1098-1104 [PMID: 21920001 DOI: 10.1111/j.1365-2982.2011.01771.x]
88. Chiba T, Yamamoto K, Sato S, Suzuki K. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol 2013; 6: 123-128 [PMID: 23922505 DOI: 10.2147/CEG.S32721]
89. Tack J, Janssen P, Wouters M, Boeckxstaens G. Targeting serotonin synthesis to treat irritable bowel syndrome. Gastroenterology 2011; 141: 420-422 [PMID: 21703266 DOI: 10.1053/j.gastro.2011.06.024]
90. Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O' Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 2008; 325: 47-55 [PMID: 18192499 DOI: 10.1124/jpet.107.132670]
91. Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil 2011; 23: 193-200 [PMID: 21159063 DOI: 10.1111/j.1365-2982.2010.01643.x]
92. Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A, Gershon MD. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011; 141: 507-516 [PMID: 21684281 DOI: 10.1053/j.gastro.2011.05.005]
93. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 2010; 77 : 69-78 [PMID: 19808995 DOI: 10.1124/mol.109.061051]
94. Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008; 78: 180-186 [PMID: 19092244 DOI: 10.1159/000185719]
95. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-858 [PMID: 15316000 DOI: 10.1001/jama.292.7.852]
96. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95 : 3503-3506 [PMID: 11151884 DOI: 10.1111/j.1572-0241.2000.03368.x]
97. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-419 [PMID: 12591062 DOI: 10.1111/j.1572-0241.2003.07234.x]
98. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551 [PMID: 15765388 DOI: 10.1053/j.gastro.2004.11.050]
99. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007; 25: 1271-1281 [PMID: 17509095 DOI: 10.1111/j.1365-2036.2007.03313.x]
100. Connor BA. Sequelae of traveler's diarrhea: focus on post-infectious irritable bowel syndrome. Clin Infect Dis 2005; 41 Suppl 8: S577-S586 [PMID: 16267722 DOI: 10.1086/432956]
101. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006; 51 : 1297-1301 [PMID: 16832617 DOI: 10.1007/s10620-006-9104-6]
102. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs 2005; 65: 1697-1713 [PMID: 16060706 DOI: 10.2165/00003495-2005651 20-00011]
103. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-333 [PMID: 16454838 DOI: 10.1111/j.1572-0241.2006.00458.x]
104. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145 : 557-563 [PMID: 17043337 DOI: 10.7326/0003-4819-145-8-200610170-00004]
105. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
106. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35; quiz 36 [PMID: 22045120 DOI: 10.1038/ajg.2011.355]
107. Clouse RE, Alpers DH, Hockenbery DM, DeSchryver-Kecskemeti K. Pericrypt eosinophilic enterocolitis and chronic diarrhea. Gastroenterology 1992; 103: 168-176 [PMID: 1612324]
108. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, Bartesaghi G, Canovi B, Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-252 [PMID: 19438846 DOI: 10.1111/j.1365-2036.2009.04041.x]
109. Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 374-383 [PMID: 21671966 DOI: 10.1111/j.1365-2036.2011.04732.x]
110. Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome - a pilot study. Scand J Gastroenterol 2012; 47 : 1159-1164 [PMID: 22783919 DOI: 10.3109/00365521.2012.694903]
111. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001; 96 : 1499-1506 [PMID: 11374689 DOI: 10.1111/j.1572-0241.2001.03804.x]
112. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123 : 2108-2131 [PMID: 12454866 DOI: 10.1053/gast.2002.37095]
113. Clemens CH, Samsom M, Roelofs JM, van Berge Henegouwen GP, Smout AJ. Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1838-1843 [PMID: 12907341 DOI: 10.1111/j.1572-0241.2003.07541.x]
114. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-361 [PMID: 11207510 DOI: 10.1046/j.1365-2036.2001.00937.x]
115. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-147 [PMID: 10896640 DOI: 10.7326/0003-4819-133-2-200007180-00013]
116. Talley NJ. Drug therapy options for patients with irritable bowel syndrome. Am J Manag Care 2001; 7: S261-S267 [PMID: 11474911]
117. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 547-553 [PMID: 20128021 DOI: 10.3748/wjg.v16.i5.547]
118. Everitt H, Moss-Morris R, Sibelli A, Tapp L, Coleman N, Yardley L, Smith P, Little P. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol 2013; 13: 68 [PMID: 23602047 DOI: 10.1186/1471-230X-13-68]
119. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004; 10: 3561-3568 [PMID: 15579053 DOI: 10.2174/1381612043382972]
120. Evangelista S, Giachetti A, Chapelain B, Neliat G, Maggi CA. Receptor binding profile of Otilonium bromide. Pharmacol Res 1998; 38: 111-117 [PMID: 9721598 DOI: 10.1006/phrs.1998.0340]
121. Lindqvist S, Hernon J, Sharp P, Johns N, Addison S, Watson M, Tighe R, Greer S, Mackay J, Rhodes M, Lewis M, Stebbings W, Speakman C, Evangelista S, Johnson I, Williams M. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol 2002; 137: 1134-1142 [PMID: 12429587 DOI: 10.1038/sj.bjp.0704942]
122. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccarato R. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998; 12 : 1003-1010 [PMID: 9798806 DOI: 10.1046/j.1365-2036.1998.00397.x]
123. Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, Corazziari E, Badiali G, Pescatori M, Anastasio G. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol 1991; 23: 60-63 [PMID: 1756285]
124. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313 [PMID: 19008265 DOI: 10.1136/bmj.a2313]
125. Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 432-442 [PMID: 21679214 DOI: 10.1111/j.1365-2036.2011.04730.x]
126. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-158 [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328.x]
127. Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17 : 402-410 [PMID: 22148110 DOI: 10.5056/jnm.2011.17.4.402]
128. Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T. Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial. J Neurogastroenterol Motil 2012; 18: 317-323 [PMID: 22837880 DOI: 10.5056/jnm.2012.18.3.317]
129. Mizuta Y, Takahashi T, Owyang C. Nitrergic regulation of colonic transit in rats. Am J Physiol 1999; 277: G275-G279 [PMID: 10444440]
130. Luo ZD, Cizkova D. The role of nitric oxide in nociception. Curr Rev Pain 2000; 4: 459-466 [PMID: 11060592 DOI: 10.1007/s11916-000-0070-y]
131. Fritz E, Hammer J, Schmidt B, Eherer AJ, Hammer HF. Stimulation of the nitric oxide-guanosine 3′, 5′-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. Am J Gastroenterol 2003; 98 : 2253-2260 [PMID: 14572576 DOI: 10.1111/j.1572-0241.2003.07661.x]
132. Gonc¸alves de Medeiros MT, de Oliveira RB, dos Santos AA, de Leopoldino DM, Lima MC, Nobre RA, Nobre e Souza MÂ. The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 577-586 [PMID: 22229478 DOI: 10.1111/j.1365-2036.2011.04977.x]
133. Holzer P . Opioid receptors in the gastrointestinal tract. Regul Pept 2009; 155: 11-17 [PMID: 19345246 DOI: 10.1016/j.regpep.2009.03.012]
134. Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ. Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/ μ opioid receptor antagonist. Br J Pharmacol 2012; 167 : 1111-1125 [PMID: 22671931 DOI: 10.1111/j.1476-5381.2012.02068.x]
135. Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013; 145: 329-338. e1 [PMID: 23583433 DOI: 10.1053/j.gastro.2013.04.006]
136. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28 : 239-249 [PMID: 18466359 DOI: 10.1111/j.1365-2036.2008.03730.x]
137. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202 [PMID: 12037135 DOI: 10.1124/pr.54.2.161]
138. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007; 293: G137-G145 [PMID: 17395895 DOI: 10.1152/ajpgi.00565.2006]
139. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 2011; 141: 1638-1647.e1-7 [PMID: 21803011 DOI: 10.1053/j.gastro.2011.07.036]
140. Hellström PM, Grybäck P, Jacobsson H. The physiology of gastric emptying. Best Pract Res Clin Anaesthesiol 2006; 20: 397-407 [PMID: 17080692 DOI: 10.1016/j.bpa.2006.02.002]
141. Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008; 20: 649-659 [PMID: 18298441 DOI: 10.1111/j.1365-2982.2007.01079.x]
142. Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M, Greenberg GR. Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J Clin Endocrinol Metab 2002; 87: 3078-3083 [PMID: 12107204 DOI: 10.1210/jcem.87.7.8584]
143. Hellström PM, Hein J, Bytzer P, Björnssön E, Kristensen J, Schambye H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009; 29: 198-206 [PMID: 18945254 DOI: 10.1111/j.1365-2036.2008.03870.x]
144. Camilleri M, Vazquez-Roque M, Iturrino J, Boldingh A, Burton D, McKinzie S, Wong BS, Rao AS, Kenny E, Ma˚nsson M, Zinsmeister AR. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: G120-G128 [PMID: 22517769 DOI: 10.1152/ajpgi.00076.2012]
145. Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59 : 1213-1221 [PMID: 20650926 DOI: 10.1136/gut.2010.213108]
146. Santos J, Alonso C, Guilarte M, Vicario M, Malagelada JR. Targeting mast cells in the treatment of functional gastrointestinal disorders. Curr Opin Pharmacol 2006; 6 : 541-546 [PMID: 16956793 DOI: 10.1016/j.coph.2006.08.001]
147. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hébuterne X. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473 [PMID: 18194987 DOI: 10.1136/gut.2007.127068]
148. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702 [PMID: 14988823 DOI: 10.1053/j.gastro.2003.11.055]
149. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21 : 71-78 [PMID: 16706815 DOI: 10.1111/j.1440-1746.2005.04143.x]